

ONCOLOGY PHARMA LIMITED

REGISTERED NO. 06926307

**ABBREVIATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED SEPTEMBER 30th 2011**



ONCOLOGY PHARMA LIMITED

INDEX TO THE ABBREVIATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED SEPTEMBER 30th 2011

CONTENTS	PAGES
Abbreviated balance sheet	1
Notes to the abbreviated accounts	2 - 3

ONCOLOGY PHARMA LIMITED

ABBREVIATED BALANCE SHEET AS AT SEPTEMBER 30th 2011


	Notes	2010 £	2009 £
FIXED ASSETS			
Tangible assets	2	213	284
CURRENT ASSETS			
Debtors		133	0
Cash at bank and in hand		175	217
		<u>308</u>	<u>217</u>
CREDITORS: Amounts falling due within one year	3	<u>10,171</u>	<u>4,147</u>
NET CURRENT ASSETS		(9,863)	(3,930)
TOTAL ASSETS LESS CURRENT LIABILITIES		(9,650)	(3,646)
PROVISION FOR LIABILITIES AND CHARGES		<u>0</u>	<u>0</u>
NET ASSETS		<u>£ (9,650)</u>	<u>£ (3,646)</u>
Financed by:			
CAPITAL AND RESERVES			
EQUITY INTERESTS:			
Called up share capital	4	100	100
Profit and loss account		<u>(9,750)</u>	<u>(3,746)</u>
		<u>£ (9,650)</u>	<u>£ (3,646)</u>

The director considers that for the year ended September 30th, 2011 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies. No member or members have deposited a notice requesting an audit for the current financial year under section 476 of the Act.

The director acknowledges his responsibilities for ensuring that the company keeps accounting records which comply with the provisions of the Companies Act 2006 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the financial year in accordance with the requirements of the Companies Act 2006.

These abbreviated financial statements are prepared in accordance with the provisions applicable to companies subject to the small companies' regime and the Financial Reporting Standard for Smaller Entities (effective April 2008).

December 07, 2011


N. NAGEL

The notes on pages 2 to 3 form part of these financial statements

ONCOLOGY PHARMA LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS

1. ACCOUNTING POLICIES

BASIS OF ACCOUNTING

The financial statements have been prepared under the historical convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008)

TURNOVER

Turnover represents the value of goods and services invoiced to customers during the year, excluding value added tax

TANGIBLE FIXED ASSETS

Depreciation of tangible fixed assets has been calculated to write off the assets at rates based on the estimated useful lives of the assets. The following annual rates of depreciation used:

Office equipment	25% reducing balance basis
------------------	----------------------------

DEFERRED TAXATION

Provision has been made using the liability method for taxation, which is deferred due to depreciation allowances and other timing differences. No deferred taxation is recognised unless the amounts are material.

ONCOLOGY PHARMA LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS - continued

2. TANGIBLE FIXED ASSETS

	At 01/10/10 £	Additions £	Disposals £	At 30/09/11 £
COST				
Office equipment	<u>379</u>	<u>-</u>	<u>-</u>	<u>379</u>
	<u>379</u>	<u>-</u>	<u>-</u>	<u>379</u>
	At 01/10/10 £	Provided £	Disposals £	At 30/09/11 £
DEPRECIATION				
Office equipment	<u>95</u>	<u>71</u>	<u>-</u>	<u>166</u>
	<u>95</u>	<u>71</u>	<u>-</u>	<u>166</u>
	At 01/10/10			At 30/09/11
TOTAL NET BOOK VALUE	<u>£ 284</u>			<u>£ 213</u>

3. CREDITORS: Amounts falling due within one year

Creditors amounts falling due within one year include no secured liabilities

4. SHARE CAPITAL

	2011 £	2010 £
Authorised		
100 Ordinary Shares of £1 each	<u>100</u>	<u>100</u>
Issued and fully paid		
100 Ordinary shares of £1 each	<u>100</u>	<u>100</u>